The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Participants With Untreated Mantle Cell Lymphoma
Official Title: A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
Study ID: NCT04002297
Brief Summary: This is a randomized study to compare the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreated participants with mantle cell lymphoma (MCL) who are not eligible for stem cell transplantation.
Detailed Description:
Minimum Age: 60 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
National Hospital Organization Nagoya Medical Center, Nagoyashi, Aichi, Japan
Toyohashi Municipal Hospital, Toyohashi, Aichi, Japan
Chiba Cancer Center, Chibashi, Chiba, Japan
Kurume University Hospital, Kurume, Fukuoka, Japan
Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital, Hiroshimashi, Hiroshima, Japan
Kanagawa Cancer Center, Yokohamashi, Kanagawa, Japan
Yokohama Municipal Citizens Hospital, Yokohama, Kanagawa, Japan
National Hospital Organization Kumamoto Medical Center, Kumamotoshi, Kumamoto, Japan
Tohoku University Hospital, Sendaishi, Miyagi, Japan
Kurashiki Central Hospital, Kurashikishi, Okayama, Japan
Osaka Red Cross Hospital, Osakashi, Osaka, Japan
National Cancer Center Hospital, Chuoku, Tokyo, Japan
University Hospital, Kyoto Prefectural Univ of Medicine, Kyoto, , Japan
National Hospital Organization Okayama Medical Center, Okayama, , Japan
Osaka Metropolitan University Hospital, Osaka, , Japan
Tokyo Medical and Dental University Hospital, Tokyo, , Japan